prikaz prve stranice dokumenta Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
  Download
PDF 2.6 MB
Scientific paper - Original scientific paper
Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
Frontiers in Neurology, 10 (2019); https://doi.org/10.3389/fneur.2019.00253
Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; Seze, Jérôme de; Cruz, Dionisio Dela; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; Wijmeersch, Bart Van More authors...

Cite this document

Barclay, K., Carruthers, R., Traboulsee, A., Bass, A. D., LaGanke, C., Bertolotto, A. ... Wijmeersch, B. V. (2019). Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology, 10.. doi: 10.3389/fneur.2019.00253

Barclay, Krista, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology, vol. 10, 2019. https://doi.org/10.3389/fneur.2019.00253

Barclay, Krista, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology 10 (2019). https://doi.org/10.3389/fneur.2019.00253

Barclay, K., et al. (2019) 'Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings', Frontiers in Neurology, 10. doi: 10.3389/fneur.2019.00253

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, and sur.. Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology [Internet]. 2019 March 22 [cited 2024 October 07];10. doi: 10.3389/fneur.2019.00253

K. Barclay, et al., "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings", Frontiers in Neurology, vol. 10, March 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:548907. [Accessed: 07 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
AuthorKrista Barclay
AuthorRobert Carruthers
AuthorAnthony Traboulsee
AuthorAnn D. Bass
AuthorChristopher LaGanke
AuthorAntonio Bertolotto
AuthorAaron Boster
AuthorElisabeth G. Celius
AuthorJérôme de Seze
AuthorDionisio Dela Cruz
AuthorMario Habek
AuthorJong-Mi Lee
AuthorVolker Limmroth
AuthorSven G. Meuth
AuthorCelia Oreja-Guevara
AuthorPatricia Pagnotta
AuthorCindy Vos
AuthorTjalf Ziemssen
AuthorDarren P. Baker
AuthorBart Van Wijmeersch
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleFrontiers in Neurology
Numberingvol. 10
p-ISSN1664-2295
DOIhttps://doi.org/10.3389/fneur.2019.00253
URN:NBNurn:nbn:hr:105:548907
Publication2019-03-22
Document URLhttp://doi.org/10.3389/fneur.2019.00253
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:23:51